Search Results
Jun 02, 2026, 07:00 ET Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
LS-LBP-002.About Lishan Biotech:Lishan Biotech is a biotechnology company focused on the development of live biotherapeutic products (LBPs). We aim to address the substantial unmet clinical needs for complex diseases including inflammatory bowel disease, oncology and neurological disorders.
More news about: Evogene
Jan 09, 2026, 10:30 ET Human Microbiome Drugs Market worth $2.13 billion by 2031 | MarketsandMarkets™
An expanding pool of innovative SMEs, a maturing pipeline for microbiome modalities, and a growing inclination toward live biotherapeutic products (LBPs) and next-generation microbial therapies are notable factors driving market momentum. The US is equipped with progressive regulatory frameworks, including
More news about: MarketsandMarkets
Dec 17, 2025, 10:30 ET Human Microbiome Manufacturing Services worth $0.27 million by 2031 | MarketsandMarkets™
In September 2024, Lonza expanded its microbial manufacturing capacity in Germany, scaling up its ability to produce live biotherapeutic products (LBPs). This expansion enhances Lonza's ability to meet the rising demand for clinical- and commercial-scale microbiome and biologics manufacturing.By
More news about: MarketsandMarkets
Dec 10, 2025, 09:00 ET Siolta Therapeutics Announces Upcoming Late Breaking Oral Presentation of Results from the Phase 2 ADORED trial at 2026 AAAAI meeting
Dec. 10, 2025 /PRNewswire/ -- Siolta Therapeutics, a biotechnology company developing first-in-class live biotherapeutic products (LBPs), today announced that its abstract describing the one year results from the company's Phase 2 ADORED clinical trial of STMC-103H in infant subjects
More news about: Siolta Therapeutics
Nov 17, 2025, 07:00 ET Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Nov. 17, 2025 /PRNewswire/ -- Siolta Therapeutics, a clinical-stage biotech company developing first-in-class live biotherapeutic products (LBPs), today announced positive top-line results from the Phase 2 ADORED study (Allergic Disease Onset pREvention stuDy)
More news about: Siolta Therapeutics